Ozempic Gastroparesis Settlement: New Jersey Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Legal Advocacy

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This broad educational heritage has empowered individuals to make informed decisions about their well-being, from routine screenings to complex therapeutic interventions. Within this context, the public has grown accustomed to accessing reliable, neutral guidance on a wide array of health topics, including the benefits and risks associated with pharmaceutical treatments. As this informational landscape evolves, a more specific area of concern has emerged: the potential for certain widely prescribed medications to be associated with unintended adverse effects. Among these, the use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has drawn attention for its efficacy in managing type 2 diabetes and weight loss. However, reports have surfaced linking these drugs to gastrointestinal complications, including gastroparesis—a condition characterized by delayed gastric emptying. This shift in focus from general health education to the nuanced risks of pharmaceutical exposure represents a natural progression in public health discourse. For individuals who have experienced such complications, the transition from general awareness to personal concern often necessitates legal guidance. In New Jersey, those affected by Ozempic-related gastroparesis may seek the expertise of an injury lawyer to navigate the complexities of potential settlements, marking a pivot from informational heritage to actionable advocacy.

Understanding the Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of a mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation of gastroparesis often overlaps with common gastrointestinal complaints, making diagnosis challenging. Definitive diagnosis typically requires gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The link between Ozempic and gastroparesis is grounded in the drug's pharmacology: GLP-1 receptor agonists delay gastric emptying as part of their glucose-lowering effect, and in susceptible individuals, this effect can become pathological, resulting in symptomatic gastroparesis. Evidence from clinical trials demonstrates a significantly higher incidence of gastrointestinal adverse reactions among patients receiving Ozempic compared to placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which aligns with the mechanistic pathway of delayed gastric emptying.

Additional Gastrointestinal Adverse Reactions and Warning Adequacy

Additional gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these events are less common, they contribute to the overall gastrointestinal burden and may precede or coexist with gastroparesis. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a separate warning or caution. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of the potential for this serious complication. This gap in risk communication is central to settlement-related considerations for affected patients.

Settlement Considerations for Ozempic-Related Gastroparesis in New Jersey

For patients who have developed gastroparesis after using Ozempic, settlement considerations involve several factors. First, the timeline between exposure and documented harm is important: gastroparesis symptoms often emerge during dose escalation or after prolonged use, but the exact latency can vary. Second, the severity of the condition, including the need for hospitalization, nutritional support, or surgical intervention, influences the potential compensation. Third, the adequacy of the manufacturer's warnings is a key legal question. If the label did not sufficiently alert prescribers and patients to the risk of gastroparesis, the manufacturer may be held liable for failure to warn. In New Jersey, where many pharmaceutical product liability cases are litigated, an Ozempic gastroparesis injury lawyer can help affected individuals navigate the legal process. Settlement amounts may cover medical expenses, lost wages, pain and suffering, and other damages. In summary, the evidence supports a mechanistic link between Ozempic and gastroparesis through delayed gastric emptying, with clinical trial data showing a high incidence of gastrointestinal adverse reactions. The adequacy of warnings is questionable, as the label does not specifically address gastroparesis. Patients who have suffered this harm should consult with a qualified attorney to explore their legal options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In some individuals, this effect can become pathological, leading to gastroparesis—a condition of delayed gastric emptying without mechanical obstruction. Clinical trials show a significantly higher incidence of gastrointestinal adverse reactions in Ozempic users compared to placebo, with dose-dependent increases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What settlement options are available for Ozempic gastroparesis patients in New Jersey?

Patients in New Jersey who developed gastroparesis after using Ozempic may pursue a product liability claim, particularly for failure to warn. Settlement amounts can cover medical expenses, lost wages, pain and suffering, and other damages. Consulting an experienced Ozempic gastroparesis injury lawyer is recommended to evaluate the case and navigate the legal process.

Does the Ozempic label warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly list gastroparesis as a separate warning or caution. The label notes serious hypersensitivity reactions but lacks a specific warning for gastroparesis, which may be a critical gap in risk communication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.